Revotek Starts Trial of Stem Cell 3D Printing Product for Arterial Disease
publication date: Feb 21, 2022
Chengdu Revotek was approved to start a clinical trial of its autologous stem cell 3D bioprinting product for patients with Peripheral Artery Disease (PAD). Established in 2014, Revotek is developing REVOVAS, a universal bio-ink that allows scaffold-free bioprinting. The product itself is made up of Revotek's BioBricks®, a complex of cells and biomaterials that includes seed cells, a nuclear layer and a shell layer. The clinical study, which will be conducted in Chengdu's West China Hospital, is Revotek's first stem cell 3D bioprinting product to start human trials. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.